SCHEMBL680912

SCHEMBL680912

CCOC(=O)C1C(=O)CC[C@H]1C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.41
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
CYP2D6 P10635 2/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C19 P33261 1/20 0.39
TP53 P04637 1/20 0.39
ALOX12 P18054 1/20 0.39
TLR4 O00206 1/20 0.38
KDM4E B2RXH2 3/20 0.38
MAPT P10636 2/20 0.38
GAA P10253 1/20 0.38
HPGD P15428 1/20 0.38
HSD17B10 Q99714 1/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
HTT P42858 2/20 0.38
POLB P06746 1/20 0.38
TSHR P16473 1/20 0.37
LMNA P02545 1/20 0.37
CASP1 P29466 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1262342 1.00 ALDH1A1 (0.41) ALDH1A1MEN1KMT2ACYP2D6CYP1A2
SCHEMBL27905418 1.00 ALDH1A1 (0.41) ALDH1A1MEN1KMT2ACYP2D6CYP1A2
SCHEMBL5796691 0.90 ALDH1A1 (0.42) ALDH1A1MEN1KMT2ACYP2D6CYP1A2
SCHEMBL6904973 0.90 ALDH1A1 (0.39) ALDH1A1MEN1KMT2ACYP2D6CYP1A2
SCHEMBL30410792 0.87 CYP2D6 (0.46) ALDH1A1MEN1KMT2ACYP2D6TLR4
SCHEMBL10112419 0.84 TLR4 (0.32) TP53TLR4
SCHEMBL1149817 0.83 MAPT (0.38) ALDH1A1MEN1KMT2ACYP2D6TP53
SCHEMBL1415765 0.83 ALDH1A1 (0.46) ALDH1A1MEN1KMT2ACYP2D6CYP1A2
SCHEMBL23856961 0.82 ALDH1A1 (0.41) ALDH1A1MEN1KMT2ACYP2D6TP53
SCHEMBL28993122 0.81 ALDH1A1 (0.40) ALDH1A1MEN1KMT2ACYP2D6CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250152588-A1 HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS ARRAY BIOPHARMA INC (US) 2025-05-15 US disclosed
EP-4402126-A1 AHR AGONISTS Eli Lilly and Company (US) 2024-07-24 EP disclosed
US-12037322-B2 AHR agonists ELI LILLY AND COMPANY (US) 2024-07-16 US disclosed
CN-118215654-A AHR agonists 伊莱利利公司 2024-06-18 CN disclosed
US-20230127797-A1 AHR AGONISTS ELI LILLY AND COMPANY 2023-04-27 US disclosed
WO-2023039278-A1 AHR AGONISTS ELI LILLY AND COMPANY (US) 2023-03-16 WO disclosed
CN-111303053-B Cyclopenta [ d ] pyrimidine compound and pharmaceutically acceptable salt, solvate or prodrug thereof and application 中国海洋大学 2023-01-17 CN disclosed
US-20220226326-A1 HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2022-07-21 US disclosed
CN-112915092-A Combinations of AKT inhibitor compounds and abiraterone and methods of use 基因泰克公司 2021-06-08 CN disclosed
CN-111643504-A Combinations of AKT inhibitor compounds and chemotherapeutic agents and methods of use 基因泰克公司 2020-09-11 CN disclosed
US-20100292244-A1 HYDROXYLATED PYRIMIDYL CYCLOPENTANE AS AKT PROTEIN KINASE INHIBITOR ARRAY BIOPHARMA INC. (US) 2010-11-18 US disclosed
WO-2009089453-A9 HYDROXYLATED PYRIMIDYL CYCLOPENTANE AS AKT PROTEIN KINASE INHIBITOR ARRAY BIOPHARMA INC. (US) 2009-11-05 WO disclosed
WO-2009006569-A1 PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2009-01-08 WO disclosed
WO-2009006567-A2 PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2009-01-08 WO disclosed
US-20080058327-A1 4-piperazinyl-5H-6,7-dihydrocyclopenta(d)pyrimidines; Hyperproliferative diseases such as cancer GENENTECH, INC. 2008-03-06 US disclosed
US-20080058327-A1 4-piperazinyl-5H-6,7-dihydrocyclopenta(d)pyrimidines; Hyperproliferative diseases such as cancer GENENTECH, INC. 2008-03-06 US disclosed
US-20080051399-A1 HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS ARRAY BIOPHARMA INC. 2008-02-28 US disclosed
US-20080051399-A1 HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS ARRAY BIOPHARMA INC. 2008-02-28 US disclosed
WO-2008006040-A1 HYDROXYLATED AND METHOXYLATED CYCLOPENTA [D] PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2008-01-10 WO disclosed
WO-2008006032-A1 CYCLOPENTA [D] PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2008-01-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080058327-A1 4-piperazinyl-5H-6,7-dihydrocyclopenta(d)pyrimidines; Hyperproliferative diseases such as cancer PIK3CA, DPYD, CDK2 ALDH1A1 1144/4885MEN1 2764/4885KMT2A 1379/4885
US-20080051399-A1 HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS AKT1, AKT2, AKT1S1 ALDH1A1 1715/4885MEN1 1677/4885KMT2A 1884/4885
US-20220226326-A1 HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS AKT1, AKT2, AKT1S1 ALDH1A1 1715/4885MEN1 1677/4885KMT2A 1884/4885
US-20100292244-A1 HYDROXYLATED PYRIMIDYL CYCLOPENTANE AS AKT PROTEIN KINASE INHIBITOR AKT1, AKT2, PIK3CA ALDH1A1 1197/4885MEN1 2471/4885KMT2A 2125/4885
US-12037322-B2 AHR agonists AHR, ARNT, RORC ALDH1A1 724/4885MEN1 4802/4885KMT2A 892/4885
US-20230127797-A1 AHR AGONISTS AHR, ARNT, RORC ALDH1A1 724/4885MEN1 4802/4885KMT2A 892/4885
US-20250152588-A1 HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS AKT1, AKT2, AKT1S1 ALDH1A1 1715/4885MEN1 1677/4885KMT2A 1884/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.